Fresenius gains access to up to 37 biosimilar candidates via WuXi & Supernus-Indivior merger closes

Fresenius gains exclusive access to up to 37 biosimilar candidates through WuXi Biologics, with initial development expected on biosimilars of polatuzumab vedotin and teprotumumab. Supernus and Indivior complete their merger, leaving former Indivior holders with about 56.5% of Supernus, Inc., while a separate $1 billion dividend is partly funded by a loan to the combined company. In neurology, Bright Minds reports an FDA partial hold on a planned BMB-101 Phase 2 study, Tiziana reports INFORM-MS data for foralumab, and Novartis ends a BrainTransporter deal with BioArctic. This delayed November 2 edition cites Samsung Biologics' later November 5 definitive figures: 97.66% of PolyPeptide's issued share capital and voting rights tendered.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.